Top Abstract Purchase Related
Home
>
Node
>
Subnode

DNA topoisomerases and topoisomerase inhibitors

Giaccone, G.

Pathologie-Biologie 42(4): 346-352

1994

ISSN/ISBN: 0369-8114
PMID: 7808789
Document Number: 429926
DNA topoisomerases are ubiquitous nuclear enzymes, essential for several steps of DNA metabolism. They have recently been shown to be specific targets of a number of anticancer agents. In this review are discussed the most recent discoveries in the physiology and the molecular biology of DNA topoisomerases, and the mechanism of interaction with drugs. In addition, alterations of DNA topoisomerases are also described, as potential responsible of drug resistance.

Document emailed within 1 workday
Secure & encrypted payments

Boege, F. 1996: Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects European Journal of Clinical Chemistry and Clinical Biochemistry 34(11): 873-888
Gutzler, F. 1996: New drugs. Topoisomerase inhibitors Zentralblatt für Gynakologie 118(10): 579
Verschraegen, C.F.; Kudelka, A.P.; Kavanagh, J.J. 1998: Topoisomerase-i inhibitors in gynaecologic tumours Annals of the Academy of Medicine Singapore 27(5): 683-687
Alpan, A.Selcen.; Gunes, H.Semih.; Topcu, Z. 2007: 1H-Benzimidazole derivatives as mammalian DNA topoisomerase I inhibitors Acta Biochimica Polonica 54(3): 561-565
Rothenberg, M.L.; Blanke, C.D. 1999: Topoisomerase i inhibitors in the treatment of colorectal cancer Seminars in Oncology 26(6): 632-639
Cho, L.C.; Choy, H. 2004: Topoisomerase i inhibitors in the combined-modality therapy of lung cancer Oncology 18(7 Suppl 4: 29-39
Fukuoka, M. 2001: Role of topoisomerase i inhibitors in small-cell lung cancer Oncology 15(7 Suppl 8: 9-13
Wang, W.; Tse-Dinh, Y-Ching. 2019: Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy Current Topics in Medicinal Chemistry 19(9): 730-740
Chavalitshewinkoon-Petmitr, P.; Worasing, R.; Wilairat, P. 2001: Partial purification of mitochondrial DNA topoisomerase II from Plasmodium falciparum and its sensitivity to inhibitors Southeast Asian Journal of Tropical Medicine and Public Health 32(4): 733-738
Meikle, I.; Cummings, J.; Macpherson, J.S.; Smyth, J.F. 1995: Identification of anthracenyl-dipeptide conjugates as novel topoisomerase i and Ii inhibitors and their evaluation as potential anticancer drugs Anti-Cancer Drug Design 10(7): 515-527
Robson, C.N.; Hoban, P.R.; Harris, A.L.; Hickson, I.D. 1987: Cross-sensitivity to topoisomerase Ii inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines Cancer Research 47(6): 1560-1565
Meliksetian, M.B.; Berezkina, E.V.; Pavlenko, M.A.; Grinchuk, T.M. 1999: Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase Ii inhibitors adriamycin and etoposide Tsitologiia 41(7): 615-621
Coleman, L.W.; Bronstein, I.B.; Holden, J.A. 2001: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas Anticancer Research 21(2a): 1167-1172
Herzog, C.E.; Holmes, K.A.; Tuschong, L.M.; Ganapathi, R.; Zwelling, L.A. 1998: Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha Cancer Research 58(23): 5298-5300
Ishida, R.; Miki, T.; Narita, T.; Yui, R.; Sato, M.; Utsumi, K.R.; Tanabe, K.; Andoh, T. 1991: Inhibition of intracellular topoisomerase Ii by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors Cancer Research 51(18): 4909-4916
Harker, W.G.; Slade, D.L.; Parr, R.L.; Feldhoff, P.W.; Sullivan, D.M.; Holguin, M.H. 1995: Alterations in the topoisomerase Ii alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase Ii beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Research 55(8): 1707-1716
Kafiani, K.A.; Bronshteĭn, I.B.; Gromova, I.I.; Shakhbazian, G.K.; Timofeev, A.V. 1985: DNA-topoisomerases of animal cells Molekuliarnaia Biologiia 19(2): 438-449
Andoh, T.; Okada, K. 1989: DNA topoisomerases and resistance to anticancer agents Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(3 Part 2): 569-575
Nakano, H. 1991: Antitumor agents targeting mammalian topoisomerases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(10): 1550-1555
Hwang, J.J.; Marshall, J.L.; Rizvi, N. 2003: Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin Oncology 17(5 Suppl. 5): 46-51